|
|
|
|
|
Pancrelipase: profile and news
Axcan announces record revenue of $72.8 million for the second ... May 4, 2006 Other information Indication For treatment of cystic fibrosis, chronic pancreatitis, pancreatic duct blockage Pharmacology Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool. Mechanism Of Action The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Drug Category Enzyme replacement; enzymes (44:00.00) Brand Names/Synonyms Pancreatic alpha-amylase precursor;PA;1,4-alpha-D- glucan glucanohydrolase; Pancrease (Ortho-McNeil); Cotazym (Organon); Ku-Zyme (Koichi); Ultrase (Axcan Scandipharm); Zymase (Organon) Dosage Forms TABLET Absorption Not Available Interactions Not Available Chemical IUPAC Name Not Available Chemical Formula C5850H8902N1606O1739S49 >pancreatic triacylglycerol lipase >chymotrypsin B Half Life Not Available Drug Type Approved Drug # Accession No BIOD00067 CAS Registry Number 53608-75-6 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |